GSK Acquires Promising Liver Disease Medication in Deal Valued at Up to $2 Billion
GSK is investing up to $2 billion to acquire efimosfermin, a promising drug in late-stage trials for treating fatty liver disease, which could revolutionize care and lower healthcare costs. Source: medicalxpress.com
British pharmaceutical leader GlaxoSmithKline (GSK) has announced its strategic acquisition of an investigational drug aimed at treating a prevalent form of liver disease, in a deal that could reach up to $2 billion. The company has agreed to pay $1.2 billion upfront to Boston Pharmaceuticals, with an additional $800 million potentially earned through success-based milestones. This promising medication, efimosfermin, is currently in the final stages of clinical trials and is targeted at steatotic liver disease (SLD), which impacts approximately 5% of the global population. GSK anticipates that efimosfermin could establish itself as a new standard of care for SLD, a condition characterized by fat accumulation in the liver that can progress to severe damage and necessitate transplantation. The drug may also be effective against liver damage caused by alcohol use. GSK estimates that widespread use of efimosfermin could help prevent disease progression, potentially saving the US healthcare system between $40 billion and $100 billion over the next two decades.
SLD currently has limited therapeutic options, making this development particularly significant for patient care. The acquisition highlights GSK’s commitment to expanding its portfolio in liver health and tackling unmet medical needs in this field.
This move underscores the potential impact of efimosfermin in transforming liver disease treatment and reducing healthcare costs associated with advanced liver damage.
Source: https://medicalxpress.com/news/2025-05-gsk-buys-liver-disease-drug.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
NIH Reverses Decision to Cancel Research Grants After Court Ruling
The NIH has halted the cancellation of hundreds of research grants following a court ruling, marking a significant shift in federal research funding policies amid legal challenges.
Hidden Surgical Risks: The Impact of Alcohol Withdrawal Syndrome on Postoperative Outcomes
Recent studies reveal that alcohol withdrawal syndrome significantly impacts surgical outcomes, increasing risks, hospital stays, and costs. Early detection is vital for improved patient recovery.
Hypnosis as a Complementary Approach for Managing Dental Pain and Stress
Hypnosis shows promising potential in managing dental pain, anxiety, and chronic orofacial conditions, enhancing patient comfort, and reducing medication use. A recent review underscores the importance of integrating hypnosis into dental practice through standard protocols and training.